BR0206823A - Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo - Google Patents

Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo

Info

Publication number
BR0206823A
BR0206823A BR0206823-0A BR0206823A BR0206823A BR 0206823 A BR0206823 A BR 0206823A BR 0206823 A BR0206823 A BR 0206823A BR 0206823 A BR0206823 A BR 0206823A
Authority
BR
Brazil
Prior art keywords
vaccine composition
therapeutic
hiv
chimeric
recombinant virus
Prior art date
Application number
BR0206823-0A
Other languages
English (en)
Inventor
Enrique Iglesias Perez
Dania M Vazquez Blomquist
Carlos A Duarte Cano
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40091626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0206823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0206823A publication Critical patent/BR0206823A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"GENE QUIMéRICO, PROTEìNA QUIMéRICA, VìRUS RECOMBINANTE, COMPOSIçãO DE VACINA, USO DE UMA COMPOSIçãO DE VACINA, COMBINAçãO TERAPêUTICA OU PREVENTIVA, E, PLASMìDEO". Descreve-se genes quiméricos do HIV formados pela ligação de fragmentos de diferentes genes deste vírus, sendo que estes fragmentos contém epitopos para células T citotóxicas (CTL) ou T auxiliares do HIV-1, os quais são apresentados por uma ampla gama de antígenos do Sistema Principal de Histocompatibilidade Humano de tipo 1 (HLA- 1). A partir destes genes obtém-se poxvírus recombinantes úteis na vacinação profilática e terapêutica contra a infecção por HIV/AIDS capazes de gerar uma resposta imunológica celular protetora em animais de laboratório imunizados e sendo reconhecidos pelos linfócitos CTL de pacientes de HIV/AIDS.
BR0206823-0A 2001-02-28 2002-02-22 Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo BR0206823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010057A CU23235A1 (es) 2001-02-28 2001-02-28 POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
PCT/CU2002/000001 WO2002068654A2 (es) 2001-02-28 2002-02-22 Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana

Publications (1)

Publication Number Publication Date
BR0206823A true BR0206823A (pt) 2004-02-25

Family

ID=40091626

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0206823-0A BRPI0206823B1 (pt) 2001-02-28 2002-02-22 Gene quimérico, proteína quimérica, vírus recombinante, e, composição de vacina
BR0206823-0A BR0206823A (pt) 2001-02-28 2002-02-22 Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0206823-0A BRPI0206823B1 (pt) 2001-02-28 2002-02-22 Gene quimérico, proteína quimérica, vírus recombinante, e, composição de vacina

Country Status (16)

Country Link
US (2) US7318927B2 (pt)
EP (1) EP1371730B1 (pt)
JP (1) JP4125128B2 (pt)
KR (1) KR100920141B1 (pt)
CN (1) CN1526018B (pt)
AR (1) AR032871A1 (pt)
AT (1) ATE435916T1 (pt)
AU (1) AU2002237195B2 (pt)
BR (2) BRPI0206823B1 (pt)
CA (1) CA2430702C (pt)
CU (1) CU23235A1 (pt)
DE (1) DE60232862D1 (pt)
ES (1) ES2329768T3 (pt)
RU (1) RU2302461C2 (pt)
WO (1) WO2002068654A2 (pt)
ZA (1) ZA200304387B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
ATE494387T1 (de) 2001-11-07 2011-01-15 Mannkind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
EP1450854A2 (en) 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7638134B2 (en) * 2003-02-20 2009-12-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Insertion sites in fowlpox vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
FR2987836A1 (fr) * 2012-03-09 2013-09-13 Biomerieux Sa Peptides d'interference et procede de detection de microorganismes
EP2900259B1 (en) * 2012-09-28 2020-04-15 Kline, Ellis Glycosidase regimen for treatment of infectious disease
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP2022539417A (ja) * 2019-07-02 2022-09-08 グリットストーン バイオ インコーポレイテッド Ｈｉｖ抗原及びｍｈｃ複合体
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
CN112852749A (zh) * 2021-03-27 2021-05-28 哈尔滨元亨生物药业有限公司 高效分泌犬细小病毒单克隆抗体杂交瘤细胞株c68及利用生物反应器对其进行生产的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs

Also Published As

Publication number Publication date
WO2002068654A3 (es) 2003-03-13
RU2003128991A (ru) 2005-01-20
US7318927B2 (en) 2008-01-15
ZA200304387B (en) 2004-08-11
US20080280354A1 (en) 2008-11-13
CU23235A1 (es) 2007-09-26
ES2329768T3 (es) 2009-12-01
CA2430702C (en) 2013-07-09
KR100920141B1 (ko) 2009-10-08
CA2430702A1 (en) 2002-09-06
RU2302461C2 (ru) 2007-07-10
KR20030079946A (ko) 2003-10-10
BRPI0206823B1 (pt) 2018-08-14
DE60232862D1 (de) 2009-08-20
AR032871A1 (es) 2003-11-26
EP1371730B1 (en) 2009-07-08
JP4125128B2 (ja) 2008-07-30
JP2004518443A (ja) 2004-06-24
US20040073008A1 (en) 2004-04-15
WO2002068654A2 (es) 2002-09-06
EP1371730A2 (en) 2003-12-17
CN1526018A (zh) 2004-09-01
CN1526018B (zh) 2013-04-03
ATE435916T1 (de) 2009-07-15
AU2002237195B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
Hu et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
Takahashi et al. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
Ramsay et al. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
Hanlon et al. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors
US20070134262A1 (en) Antigens encoded by alternative reading frames from pathogenic viruses
NZ522542A (en) Synthetic peptides and uses thereof
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
DK0956360T3 (da) Poxvirusbaserede ekspressionsvektorer indeholdende heterologe inserts afledt af lentvirus
CA2408328A1 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
ES2140380T5 (es) Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
Kim et al. Development of a multicomponent candidate vaccine for HIV-1
ES2389519T3 (es) Casetes de inmunización de ADN de vif atenuados para vacunas genéticas
Stuart et al. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea
US20040223977A1 (en) Fusion peptide HIV vaccines
Fomsgaard HIV-1 DNA vaccines
Mills et al. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins
Spetz et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
BRPI0410422A (pt) materiais e processos para para imunização contra infecção por fiv
DE60238773D1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
Hamajima et al. Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate
OHISHI et al. Peptide-based bovine leukemia virus (BLV) vaccine that induces BLV-Env specific Th-1 type immunity.
Azizi et al. A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses
WO1996032483A1 (en) Immune-evading proteins

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/33

Ipc: C12N 15/49 (2006.01), C12N 15/863 (2006.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2619 DE 16-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.